Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 30, 2007 Brian Lawler	Nothing Wrong With Endo Endo Pharmaceuticals releases first-quarter financial results. Investors, take note.
The Motley Fool August 3, 2007 Brian Lawler	Endo Adjusting to Bigger Hopes The pharma announces its second-quarter financial results. As worries recede about near-term generic competition for lead drug Lidoderm, expectations for Endo have grown.
The Motley Fool October 23, 2006 Brian Lawler	Not the End for Endo An FDA decision won't hurt the maker of Lidoderm. Investors, take note.
The Motley Fool January 10, 2007 Brian Lawler	Endo's Plan to Bring In the Dough Despite little movement in the value of their shares, 2006 was an eventful year for investors in drug developer Endo Pharmaceuticals.
The Motley Fool November 6, 2007 Brian Lawler	The Two Sides of Endo It has been a mixed third quarter for Endo Pharmaceuticals. On the financial side of things the company performed well; on the research and development side, things are not as good.
The Motley Fool September 29, 2010 Brian Orelli	A Mini-Teva in the Making Generic growth by Endo Pharmaceuticals.
The Motley Fool January 19, 2007 Brian Lawler	The Best Drug Stock for 2007: Endo Pharmaceuticals This drug-maker just might be a great investment at the current price.
The Motley Fool January 30, 2008 Brian Lawler	The Endo a CEO Shares of Endo Pharmaceutical rise after its CEO, Peter Lankau, resigns.
The Motley Fool February 25, 2008 Brian Lawler	The Yin and Yang of Endo Endo Pharmaceuticals' fiscal 2007 report offered positive year-end financial results and a little bit of balance-sheet sourness.
The Motley Fool August 1, 2007 Brian Lawler	Calling Out Endo Endo Pharmaceuticals gets taken to task by an activist investor. An investment group owning 5.6% of outstanding shares is concerned with how management plans to use $700 million available to them in cash and investments.
The Motley Fool April 1, 2008 Brian Lawler	The Endo a Patent? Endo sues to protect a lead drug from generic competition.
The Motley Fool January 22, 2007 Brian Lawler	The Feds Eye Endo Endo Pharmaceuticals' sales practices for Lidoderm prompt government scrutiny. Investors don't seem too concerned.
BusinessWeek December 11, 2006 Michael Arndt	When A Winner Starts To Wane Endo is seeking to immunize itself from the slowing growth of its Lidoderm pain patch.
The Motley Fool April 30, 2007 Brian Orelli	No Pain for Endo's Investors Endo Pharmaceuticals had an impressive first quarter thanks to a new product and continued sales growth of its older brands. Investors, take note.
The Motley Fool April 16, 2008 Brian Lawler	Alpharma's Soothing Guidance Alpharma lowers its financial guidance for 2008. Investors, take note.
The Motley Fool April 30, 2008 Brian Lawler	The Start of a New Endo The drugmaker marks its first quarter under new management.
The Motley Fool March 20, 2007 Brian Lawler	A Slowdown at Endo The FDA delays a decision on expanding the label for one of Endo's drugs. Investors, take note.
The Motley Fool April 12, 2011 Arundhati Parmar	Endo Acquires Pelvic Care Firm American Medical Systems The company that began life in the pharmaceutical sector is venturing forth into devices in its quest to become more of a diversified health-care company.
Chemistry World September 2, 2013 Emma Stoye	Endo Health to buy Boca Pharmacal for $225m US speciality healthcare company Endo Health Solutions has agreed to buy Boca Pharmacal for $225 million in a bid to expand its generics business.
Chemistry World May 26, 2015 Phillip Broadwith	Endo to buy Par as generics consolidation continues Irish-headquartered firm Endo Pharmaceuticals has agreed to buy private US firm Par Pharmaceuticals in a deal worth around $8 billion in a combination of cash, shares and assumed debt.
The Motley Fool July 2, 2008 Brian Lawler	DURECT's Intriguing Little Orphan An exciting pain drug inches onward in development.
The Motley Fool January 31, 2007 Brian Lawler	Mylan on the Generic Attack Two new drug approvals for the generic drugmaker come in the midst of a changing regulatory environment. Investors, take note.
The Motley Fool December 30, 2010 Brian Orelli	That's What You Call Product Differentiation? Endo Pharma misses the mark with its treatment for low testosterone, which the Food and Drug Administration approved yesterday.
The Motley Fool February 29, 2008 Brian Lawler	NeurogesX Gets a Painful Kick in the Pants NeurogesX's lead drug fails in clinical testing.
The Motley Fool October 3, 2007 Brian Lawler	FDA Says Nay to Endo Endo Pharmaceuticals announces that the FDA issued a "not approvable" letter in response to the company's attempt to expand the label for migraine treatment Frova.
The Motley Fool September 6, 2007 Brian Lawler	NeurogesX Feels No Pain Investors reward the drugmaker for positive study results.
Chemistry World June 7, 2013 Phillip Broadwith	Job cuts at three US pharma companies Endo will shed 15% of its global workforce by mid 2014; Impax is cutting 110 manufacturing and sales positions (around 12% of its workforce); and Zogenix is laying off 55 of its 148 staff (37%).
The Motley Fool August 18, 2010 Travers & Jayson	Will Endo Pharmaceuticals Holdings Burn You? Endo Pharmaceuticals Holdings is cash flow-positive, and has been for quite some time. That's investment nirvana for biotech shareholders.
The Motley Fool June 13, 2007 Billy Fisher	The Best Drug Stock for 2007 Revisited With half of the season left, anything can happen and no lead is safe -- especially in the biotech/pharmaceutical industry. For now the leader, Endo Pharmaceutical, is head and shoulders above the rest.
The Motley Fool December 28, 2007 Brian Lawler	Endo and Alexza Team Up Endo Pharmaceuticals and Alexza Pharmaceuticals announce a collaboration deal for an early-stage Alexza drug.
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.
The Motley Fool February 8, 2008 Brian Lawler	Alpharma Doing Its Best Endo Imitation Alpharma sells one of its active pharmaceutical ingredient unit to help finance other businesses.
Chemistry World March 25, 2015 Phillip Broadwith	Valeant heads off Endo bid for Salix Valeant has flexed its acquisitive muscles to head off a rival bid for gastroenterology specialist Salix Pharmaceuticals.
Chemistry World October 10, 2014 Phillip Broadwith	Endo outbids QLT for Auxilium merger US biotech Auxilium has backed out of a merger with Canadian firm QLT, in favor of a deal with US-based Endo.
The Motley Fool June 28, 2004 Jeff Hwang	Watson Pharmaceuticals Tumbles The generic drug business at Watson Pharmaceuticals is still going strong; it's the branded products that are causing trouble.
The Motley Fool July 12, 2007 Brian Lawler	Noven's Novel Acquisition With JDS Pharmaceuticals, the company is moving toward more traditional oral drugs. Investors, take note.
The Motley Fool September 18, 2007 Brian Lawler	Direct Your Attention to DURECT Promising drug test results make DURECT a company to watch. The tiny drugmaker has a host of important milestones coming up over the next year.
The Motley Fool June 11, 2007 Brian Lawler	Endo Shows Frova Endo releases more clinical trial results for one of its compounds. It's clear that the pharma will need new indications for which to market Frova if it wants to generate substantial new sales growth for the drug. Investors, take note.
The Motley Fool September 22, 2010 Seth Jayson	Will Endo Pharmaceuticals Holdings Whiff on Revenues Next Quarter? Is Endo Pharmaceuticals sending any warning signs? Take a look at its accounts receivable and days sales outstanding for a clue.
The Motley Fool July 6, 2007 Brian Orelli	Pain-Free Phase 2 Data Anesiva's pain medication is moving up the clinical trial ladder. The Adlea results are very promising, but investors should look at the state of the entire company before investing.